bioMérieux – First-Quarter 2019 Business Review
24 April, 2019
-
Organic growth of 3.8% (at constant exchange rates and scope of consolidation)
-
€632 million in sales
-
Up 7.7% as...
-
You are here
“Global-PPS”, a survey of antibiotic use and bacterial resistance in hospitals worldwide, tops the 200,000 patients
15 April, 2019
bioMérieux, a world leader in the field of in vitro diagnostics, and the Laboratory of Medical Microbiology at the University of Antwerp announced at ECCMID (European Congress of Clinical Microbiology & Infectious Diseases) the 2018 results of the Global Point...
University of Antwerp, bioMérieux, and Wellcome Trust to coordinate VALUE-Dx, a European Public-Private Partnership to fight antimicrobial resistance through diagnostics
02 April, 2019
Antwerp (Belgium), London (UK), Marcy l’Etoile (France) – April 1, 2019 - The University of Antwerp, bioMérieux and Wellcome Trust today announced the launch of VALUE-Dx, the first Innovative Medicines Initiative (IMI) project initiated by six in vitro...
Baxter and bioMérieux announce collaboration to improve identification and treatment of acute kidney injury
19 March, 2019
Baxter International Inc. (NYSE:BAX), a global leader in acute care, and bioMérieux, a world leader in the field of in vitro diagnostics, announced an agreement to develop future biomarkers with the goal to rapidly identify and inform treatment of acute kidney injury (AKI). The...
bioMérieux – 2018 Financial Results
27 February, 2019
- Organic sales growth of 9.9% for full-year 2018:
- €2,421 million in sales
- Up 5.8% as reported
- Solid fourth-quarter performance, with organic growth of more than 10%
- Improvement in...
bioMérieux acquires Invisible Sentinel, a US-based company specialized in food and beverage molecular testing
07 February, 2019
bioMérieux, a global player in in vitro diagnostics and world leader in food microbiology testing, today announced the acquisition of Invisible Sentinel Inc. This company, based in Philadelphia (PA) develops, manufactures and markets innovative and...
bioMérieux receives FDA clearance for BPA and BPN culture bottles used with BACT/ALERT® VIRTUO® for quality control testing of platelets
19 December, 2018
bioMérieux, a world leader in the field of in vitro diagnostics, announces that its culture bottles BACT/ALERT® BPA and BPN have received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for quality control testing of leukocyte-...
bioMérieux launches the BIOFIRE® FILMARRAY® Pneumonia Panels with FDA clearance and CE Marking
13 November, 2018
bioMérieux, a world leader in the field of in vitro diagnostics, today announced the Food and Drug Administration (FDA) 510(k) clearance of the BIOFIRE® FILMARRAY® Pneumonia Panel and the CE-Mark of the BIOFIRE® FILMARRAY®...
bioMérieux acquires a majority stake in Hybiome and strengthens its presence both in China and in the immunoassay market
09 November, 2018
bioMérieux, a world leader in the field of in vitro diagnostics, today announces the acquisition of a majority holding in Suzhou Hybiome Biomedical Engineering Co.Ltd. This announcement follows the acquisition of a minority stake in July 2018.
Founded in...
Business review for the nine months ended September 30, 2018
18 October, 2018
- Strong sales dynamic confirmed in third quarter, with an 8.8% increase in organic sales
- Growth of 9.8% at constant exchange rates and scope of consolidation over the nine months ended September 30:
- €1,749 million in sales
- Up 4.5% as reported